Non-opioid Pain Treatment Market Recent Developments and Growth Potential
The global non-opioid pain treatment market valued at USD 13,200.6 million in 2020, and it is projected to grow at a CAGR of 16.8 % during the forecast period, as per a recent global market research by Quince Market Insights. Growing elderly population and accessible and effective non-opioid pharmaceuticals for cancer treatment are two major factors driving growth in the global non-opioid pain treatment market. Life expectancy statistics have increased globally as a result of improved healthcare facilities and the availability of advanced treatment alternatives. As a result of their greater susceptibility to disease due to decreased immune levels, the elderly population has become the largest user of preventive and predictive medication. Medication for cancer pain provides relief from severe persistent pain.
Non-opioid pain treatment market therapeutic applications are widely employed for a variety of purposes. Arthritis treatment is one of the most prevalent indications for non-opioid pain management, and the cannabis market, in particular, is seeing a significant increase in users seeking relief from the condition's discomfort. Neuropathic pain is a prevalent type of pain linked to several diseases and ailments, including cancer, diabetes, and others. Cancer treatment is frequently accompanied with significant pain, though the degree and length of this pain varies from patient to patient and is dependent on the type of cancer, its stage, and the medication given.
Cancer treatment is frequently accompanied with significant pain, though the degree and length of this pain varies from patient to patient and is dependent on the type of cancer, its stage, and the medication given. Surgical pain, dental pain, and other pain indications not covered in earlier market segments are among the others. The usage of medical cannabis has allegedly helped people with neuropathic pain control their pain better.
The global non-opioid pain treatment market is being pushed by the rising availability of simple and effective non-opioid pain medications, as well as their reduced side effects and low cost for some therapies.
Nausea and vomiting are common side effects, as are somnolence, androgen insufficiency, respiratory depression, constipation, physical dependence, and tolerance. Patients and non-medical users alike are at danger of abusing or becoming addicted to opioid drugs. For these reasons, thinking about non-opioid pain management options is a good idea. This is propelling the global non-opioid pain management market forward. The availability of sophisticated and unique treatment alternatives, as well as increased research and development activities connected to non-opioid pain treatment, are the primary factors driving the non-opioid pain treatment market forward.
The global non-opioid pain treatment market is growing due rising prevalence of diseases such as arthritis, cancer, epilepsy, dental disorders, and others that lead to chronic pain conditions such as migraine, lower back pain, osteoarthritis, fibromyalgia, localised musculoskeletal pain, and localised neuropathic pain.
Strong pain relievers are used in non-opioid pain therapy. Because of the increased addiction created by opioids, this treatment is used instead of opioids. In comparison to non-opioids medicines, they have more negative effects. Non-opioid medications are available in prescription and over-the-counter forms and are used as a first-line treatment for acute pain. With the opioid crisis and the reduction in opioid painkiller prescriptions, non-opioid pain is predicted to develop at a rapid rate.
Increasing research and development spending, undergoing clinical trials, and changes in the regulatory environment are projected to boost support for various medications, causing the non-opioids pain management market to increase.
· September 2021 - Novaremed AG (Switzerland), a privately held clinical-stage biopharmaceutical company, announced the acquisition of Metys Pharmaceuticals AG (Metys). The acquisition broadens Novaremed’s existing pipeline and adds innovative approach for non-opioid chronic pain treatment.
· July 2021 - Hyloris Pharmaceuticals SA (Belgium), announced that Maxigesic IV, a novel non-opioid pain treatment, is now available in Germany, the largest European pharmaceutical market, and Austria.
· May 2021 - Allay Therapeutics (U.S.), a non-opioid pain startup launched Phase I data showing their polymerized bupivacaine implant helped 80% of patients get off opioids 14 days after a total knee replacement
· October 2020 - Innocoll Holdings Limited (Ireland) announced the commercial launch of the XARACOLL (bupivacaine HCI) implant, a non-opioid treatment for acute post-surgical pain for up to 24 hours in adults following open inguinal hernia repair.
The major companies of the market are Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Centrexion Therapeutics (U.S.), Regeneron Pharmaceuticals (U.S), Novartis AG (Switzerland), GW Pharmaceuticals plc. (U.K.), US WorldMeds, LLC (U.S.), Cara Therapeutics (U.S.), Trait Biosciences (Canada), and Anodyne Pain, LLC (U.S.).
To know more about our Non opioid Market report please check the link below -
Check our website
You can also contact us at - email@example.com